MedTrace Logo

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

NCT03381768 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-02-24

No results posted yet for this study

Summary

An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.

Conditions

Interventions

BIOLOGICAL

PD-L2 peptide

100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.

BIOLOGICAL

PD-L2 and PD-L1 peptide

100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.

Sponsors & Collaborators

  • Lars Møller Pedersen

    lead OTHER

Principal Investigators

  • Uffe Klausen, MD · Hematological department, Herlev Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2020-02-12
Completion
2020-02-12

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381768 on ClinicalTrials.gov